Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATHE Alterity Therapeutics Limited

Closed 06-25 16:00:00 EDT

4.90

-0.16

-3.26%

盘后4.90

+0.000.00%

19:18 EDT

High5.01	Low4.87	Vol41.75K
Open4.98	D1 Closing5.07	Amplitude2.76%
Mkt Cap88.82M	Tradable Cap61.05M	Total Shares18.13M
T/O206.19K	T/O Rate0.34%	Tradable Shares12.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATHE","market":"US","secType":"STK","nameCN":"Alterity Therapeutics Limited","latestPrice":4.9,"timestamp":1782417600000,"preClose":5.065,"halted":0,"volume":41751,"hourTrading":{"tag":"盘后","latestPrice":4.9,"preClose":4.9,"latestTime":"19:18 EDT","volume":40,"amount":196.0949,"timestamp":1782429530761,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03257650542941758,"floatShares":12458172,"shares":18125693,"eps":-0.581,"marketStatus":"Closed","change":-0.165,"latestTime":"06-25 16:00:00 EDT","open":4.98,"high":5.0099,"low":4.87,"amount":206187.939765,"amplitude":0.027621,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.581,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782460800000},"marketStatusCode":5,"adr":0,"adrRate":600,"exchange":"NASDAQ","adjPreClose":5.065,"preHourTrading":{"tag":"盘前","latestPrice":5.07,"preClose":5.065,"latestTime":"04:01 EDT","volume":2,"amount":10.14,"timestamp":1782374463745,"change":0.005,"changeRate":0.000987,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.9,"preClose":4.9,"latestTime":"19:18 EDT","volume":40,"amount":196.0949,"timestamp":1782429530761,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.755261},"requestUrl":"/m/hq/s/ATHE/tweets","defaultTab":"tweets","newsList":[{"id":"2643542607","title":"Alterity Therapeutics assumed with a Buy at Ladenburg","url":"https://stock-news.laohu8.com/highlight/detail?id=2643542607","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643542607?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:57","pubTimestamp":1781611041,"startTime":"0","endTime":"0","summary":"Ladenburg analyst Caroline Palomeque assumed coverage of Alterity Therapeutics (ATHE) with a Buy rating and $10 price target Alterity is entering l...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-assumed-with-a-buy-at-ladenburg-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-assumed-with-a-buy-at-ladenburg-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","ATHE","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289968","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289968","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289968?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:24","pubTimestamp":1781177096,"startTime":"0","endTime":"0","summary":"Big Tree Cloud  shares were down 42% in Thursday premarket activity, following the previous session's 291% rally.ICZOOM Group  stock was down 33%, following Wednesday's 90% gain.Alterity Therapeutics  shares were 30% lower, following a 3.3% decline in the previous session.Haoxin  stock was down 29%, after a 73% gain Wednesday.Autozi Internet Technology  shares were down 21%, following the previous session's 27% gain.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HXHX","DSY","AZI.AU","BK4140","AZI","BK4232","ATHE","BK4139","BK4214","BK4183","BK7095","IZM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642462865","title":"Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA","url":"https://stock-news.laohu8.com/highlight/detail?id=2642462865","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642462865?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:21","pubTimestamp":1781004104,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) announced the outcome of its End-of-Phase 2 meeting with the FDA, achieving alignment on the elements of the company’s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-achieves-alignment-with-fda-on-program-for-ath434-in-msa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-achieves-alignment-with-fda-on-program-for-ath434-in-msa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2211815571.USD","LU0757428866.USD","LABU","LU0154245756.USD","BK4143","LU1815336091.USD","BK4585","BK4139","LU1923622291.USD","LU0154245673.USD","LU2125909916.SGD","LU0728928796.USD","BK4007","BK4588","ATHE","LU0053671581.USD","LENZ","MSA","LU2125909759.SGD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642446429","title":"Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2642446429","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642446429?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:05","pubTimestamp":1781003100,"startTime":"0","endTime":"0","summary":"– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration –  – FDA agrees on UMSARS Part ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/09/3308715/0/en/Alterity-Therapeutics-Achieves-Alignment-with-U-S-FDA-on-Pivotal-Phase-3-Program-for-ATH434-in-Multiple-System-Atrophy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","ATHE","LU0053671581.USD","LU2125909759.SGD","LENZ","LU2211815571.USD","LU0154245673.USD","LU0154245756.USD","MSA","LABU","BK4588","BK4007","BK4585","LU1815336091.USD","BK4139","LU0728928796.USD","BK4539","LU2125909916.SGD","LU1923622291.USD","BK4143"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634428611","title":"Alterity Therapeutics publishes quantitative susceptibility mapping MRI data","url":"https://stock-news.laohu8.com/highlight/detail?id=2634428611","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634428611?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:01","pubTimestamp":1778500868,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) announced the publication of a peer-reviewed study in NeuroImage, demonstrating that quantitative susceptibility mappi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-publishes-quantitative-susceptibility-mapping-mri-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-publishes-quantitative-susceptibility-mapping-mri-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","ATHE","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149495","title":"Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149495","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149495?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:25","pubTimestamp":1778153100,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, May  07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289852/0/en/Alterity-Therapeutics-to-Deliver-Presentations-at-Multiple-Medical-Conferences-in-May-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909759.SGD","LU0154245756.USD","BK4139","ATHE","LU0757428866.USD","LU2211815571.USD","BK4143","BK4007","LU0053671581.USD","LU0728928796.USD","LU2125909916.SGD","MSA","LU0154245673.USD","LENZ","BK4539","LU1923622291.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631631886","title":"Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2631631886","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631631886?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:25","pubTimestamp":1777548300,"startTime":"0","endTime":"0","summary":"Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSAAdvancing ATH434 toward pivotal Phase 3 program; on track for En","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284716/0/en/Alterity-Therapeutics-Releases-Appendix-4C-Q3-FY26-Quarterly-Cash-Flow-Report-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","LU0757428866.USD","LU2746668461.USD","LU0267386448.USD","LABU","LU2237443978.SGD","LU2746668974.SGD","LU0154245756.USD","LU0971096721.USD","BK4143","LU1363072403.SGD","LU1815336091.USD","KOL","BK4585","LU2237443382.USD","IE00BHPRN162.USD","BK4139","AAN","LU1923622291.USD","LU0154245673.USD","LU2125909916.SGD","IE00B1BXHZ80.USD","IE00BKVL7J92.USD","LU2237443465.HKD","LU2237443549.SGD","LU0149725797.USD","IE00BFXG1179.USD","BK4007","LU0728928796.USD","LU0882574139.USD","BK4588","IE00BZ1G4Q59.USD","BK4006","LU2237443895.HKD","ATHE","LU0170899867.USD","LU0053671581.USD","LU2237443622.USD","LENZ","MSA","CMC","BK4178","LU2125909759.SGD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629374043","title":"Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology","url":"https://stock-news.laohu8.com/highlight/detail?id=2629374043","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629374043?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:25","pubTimestamp":1776857100,"startTime":"0","endTime":"0","summary":"-ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previous","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278839/0/en/Alterity-Therapeutics-Presents-New-Analysis-of-ATH434-Phase-2-Trial-Data-in-Late-Breaking-Science-Session-of-the-American-Academy-of-Neurology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","LU0053671581.USD","LU1923622291.USD","LU0728928796.USD","LU2125909916.SGD","ATHE","BK4117","BK4107","LU0154245756.USD","BK4143","LU2125909759.SGD","MSA","AAN","LU0757428866.USD","LU0154245673.USD","LU1815336091.USD","BK4139","AFG","LU2211815571.USD","BK4007","BK4178"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628827752","title":"Alterity Therapeutics appoints Ann Cunningham to board as independent director","url":"https://stock-news.laohu8.com/highlight/detail?id=2628827752","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628827752?lang=en_us&edition=fundamental","pubTime":"2026-04-17 18:05","pubTimestamp":1776420316,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics appointed Ann Cunningham to board as independent non-executive director, effective April 17, 2026.Cunningham is founder and CEO of i Strategy Partners, a pharmaceutical consulting group focused on patient engagement strategies.Her prior senior roles include Eli Lilly, Teva Pharmaceuticals, and Otsuka America; she currently serves on board of Vistagen Therapeutics and previously served as its chief commercial officer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 17, 2026, and is solely ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL24z54J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","LU2168564149.EUR","LU1868836914.USD","SG9999015945.SGD","LU2023250504.SGD","LU0133085943.USD","BK4599","LU0198837287.USD","LU0238689110.USD","IE00BKDWB100.SGD","SG9999013999.USD","SG9999017495.SGD","LU1814569148.SGD","LU0432979614.USD","LU2237443549.SGD","LU0786609619.USD","LU2552382215.SGD","LU1023059063.AUD","LU1868836757.USD","LU1551013342.USD","LU1988902786.USD","LU2023250330.USD","LU0234572021.USD","LU1868837300.USD","LU2361045086.USD","LU0203201768.USD","LU2471134879.HKD","IE00BN29S564.USD","LU2471134523.USD","IE00BK4W5M84.HKD","LU2264538146.SGD","LU2265009873.SGD","IE00BJJMRX11.SGD","LU0354030511.USD","LU0820561818.USD","LU0708995401.HKD","LU0122379950.USD","SG9999014898.SGD","LU0158827781.USD","LU1712237335.SGD","LU2456880835.USD","LU2213496289.HKD","LU0094547139.USD","IE00BWXC8680.SGD","LU1720051017.SGD","LU1804176565.USD","LU2063271972.USD","LU2491050071.SGD","IE00BJJMRZ35.SGD","LU2756315664.SGD","LU1623119135.USD","LU1983299246.USD","SG9999001176.SGD","SG9999014880.SGD","IE0005OL40V9.USD","LU0320765059.SGD","LU0820562030.AUD","LU2168564495.EUR","LU0158827948.USD","LU1127390331.HKD","LU2491050154.USD","GB00BDT5M118.USD","LU1267930730.SGD","LU2112291526.USD","LU0385154629.USD","LU1035775433.USD","LU0079474960.USD","LU0882574139.USD","LU2360106947.USD","LU0354030438.USD","LU0106261372.USD","LU0820561909.HKD","SG9999014914.USD","LU2168563687.JPY","BK4581","BK4516","LU1366192091.USD","LU2324357040.USD","IE00B1BXHZ80.USD","LU2471134952.CNY","ELIS","LU2468319806.SGD","LU0456855351.SGD","LU2417539215.USD","LU2237443895.HKD","LU2361044949.HKD","LU0471298694.HKD","SG9999001176.USD","SGXZ99366536.SGD","LU2462157665.USD","LU2168564065.EUR","IE0001KFT4U8.USD","BK4007","LU2552382058.USD","LU1069344957.HKD","IE00BFSS7M15.SGD","LU2237443382.USD","LU1548497426.USD","LU1551013425.SGD","LU0316494557.USD","LU1064131342.USD","LU0210536198.USD","LU2361044865.SGD","LU2750360997.AUD","LU2471134796.USD","IE00BJJMRY28.SGD","LU0266013472.USD","LU0256863811.USD","LU0353189763.USD","LU0683600562.USD","LU1629891620.HKD","LU0823416689.USD","LU2896262040.SGD","BK4588","LU2271345857.HKD","LU2750360641.GBP","LU0320765992.SGD","LU0466842654.USD","BK4139","LU2111349929.HKD","LU2237443622.USD","LU0109394709.USD","LU1291159041.SGD","LU1917777945.USD","LU0225283273.USD","LU2237443465.HKD","LU0471298777.SGD","IE00BJT1NW94.SGD","LU1093756168.USD","SG9999015978.USD","IE00B7KXQ091.USD","LU0289739699.SGD","LU0640476718.USD","IE00BJLML261.HKD","LU1232071149.USD","SG9999018865.SGD","LU0943347566.SGD","LU0096364046.USD","LU0353189680.USD","LU2168564222.USD","LLII","BK4534","LU2357305700.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BKPKM429.USD","LU0672654240.SGD","IE0009355771.USD","LU2089283258.USD","LU2552382132.HKD","LU0256863902.USD","LU0964807845.USD","LU2108987350.USD","LU0097036916.USD","LU1061106388.HKD","LU0882574055.USD","SG9999015952.SGD","LLYZ","LU2211815571.USD","SGXZ31699556.SGD","LU2237443978.SGD","LU2746668461.USD","LU2602419157.SGD","LU0889565916.HKD","SG9999014906.USD","IE00B4R5TH58.HKD","BK4533","LU0787776722.HKD","LU0417517546.SGD","LU2237438978.USD","IE0004445239.USD","LU0823434740.USD","SGXZ51526630.SGD","LU2089284900.SGD","IE00BK4W5L77.USD","LU2028103732.USD","LU2461242641.AUD","LLYX","LU2023251221.USD","LU2491049909.HKD","LU1989771016.USD","IE0004445015.USD","LU1057294990.SGD","SG9999018857.SGD","LU0061475181.USD","LU0823434583.USD","IE00B1XK9C88.USD","LU0114720955.EUR","LU1868836591.USD","LU1974910355.USD","LU2087625088.SGD","LU1720051108.HKD","IE00B775H168.HKD","LU1280957306.USD","IE00B4JS1V06.HKD","LU0006306889.USD","LU1868837136.USD","LU0323591593.USD","SG9999015986.USD","IE00BFSS8Q28.SGD","BK4585","SGXZ81514606.USD","LU0109391861.USD","ATHE","LU0203202063.USD","BK7067","LU2746668974.SGD","SGXZ57979304.SGD","LU1323610961.USD","LU0689472784.USD","LU2089984988.USD","ELIL","LU1145028129.USD","LU2106854487.HKD","IE0002141913.USD","LU2756315318.SGD","LU1093756325.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627289953","title":"Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2627289953","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627289953?lang=en_us&edition=fundamental","pubTime":"2026-04-15 19:25","pubTimestamp":1776252300,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, April  15, 2026  (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274320/0/en/Alterity-Therapeutics-to-Host-Virtual-KOL-Event-to-Share-New-Insights-on-ATH434-for-the-Treatment-of-Multiple-System-Atrophy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LU0053671581.USD","BK4218","LU1923622291.USD","LU0757428866.USD","LU2125909759.SGD","HST","BK4588","KOL","LU0154245756.USD","LU0728928796.USD","BK4585","ATHE","LU0154245673.USD","BK4181","BK4139","LU1815336091.USD","LU2211815571.USD","LU2125909916.SGD","BK4143","MSA","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616530950","title":"Alterity Therapeutics appoints Daniel Claasen as chief medical advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2616530950","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616530950?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:31","pubTimestamp":1772627513,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) announced that Daniel Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-appoints-daniel-claasen-as-chief-medical-advisor-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-appoints-daniel-claasen-as-chief-medical-advisor-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","ATHE","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616530462","title":"Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2616530462","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616530462?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:25","pubTimestamp":1772627100,"startTime":"0","endTime":"0","summary":"– Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise –MELBOURNE, Australia and SAN FRANCISCO, March  04, 2026  (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249241/0/en/Alterity-Therapeutics-Appoints-Daniel-O-Claassen-M-D-M-S-as-Chief-Medical-Advisor.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","BK4539","LU1923622291.USD","LU2211815571.USD","LU2125909916.SGD","LU0053671581.USD","LU1815336091.USD","BK4139","LU2125909759.SGD","LENZ","MSA","BK4143","LU0728928796.USD","BK4007","ATHE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616334733","title":"Alterity Therapeutics recognizes MSA Awareness Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2616334733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616334733?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:32","pubTimestamp":1772454777,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) recognizes Multiple System Atrophy, MSA, Awareness Month this March and the importance of raising awareness for a rare...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-recognizes-msa-awareness-month-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-recognizes-msa-awareness-month-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2125909759.SGD","BK4143","BK4539","LU0053671581.USD","LENZ","BK4007","LU0757428866.USD","LU2125909916.SGD","ATHE","MSA","LU1815336091.USD","LU2211815571.USD","LU1923622291.USD","LU0728928796.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616330587","title":"Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2616330587","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616330587?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:25","pubTimestamp":1772454300,"startTime":"0","endTime":"0","summary":"– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/02/3247257/0/en/Alterity-Therapeutics-Recognizes-Multiple-System-Atrophy-MSA-Awareness-Month-in-March-and-the-Urgent-Need-for-Disease-Modifying-Treatments.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125909916.SGD","LU2211815571.USD","BK4539","LU0757428866.USD","LENZ","BK4143","LU2125909759.SGD","ATHE","MSA","LU1815336091.USD","BK4139","LU0053671581.USD","LU1923622291.USD","BK4007","LU0728928796.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607489630","title":"Alterity Therapeutics provides corporate update","url":"https://stock-news.laohu8.com/highlight/detail?id=2607489630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607489630?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:38","pubTimestamp":1769776723,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 Decembe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-provides-corporate-update-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-provides-corporate-update-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","ATHE","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607048316","title":"Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2607048316","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607048316?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:25","pubTimestamp":1769775900,"startTime":"0","endTime":"0","summary":" Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced  Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multip","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/30/3229461/0/en/Alterity-Therapeutics-Appendix-4C-Q2-FY26-Quarterly-Cash-Flow-Report-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","LU1815336091.USD","LU2746668461.USD","LU0170899867.USD","LU0728928796.USD","LU0267386448.USD","LU2125909916.SGD","LU2125909759.SGD","LU2237443382.USD","BK4143","BK4006","BK4539","IE00B1BXHZ80.USD","LU0149725797.USD","LU2237443465.HKD","LU0757428866.USD","LU2237443978.SGD","MSA","LENZ","CMC","LU2237443622.USD","IE00BZ1G4Q59.USD","IE00BHPRN162.USD","BK4139","LU2237443895.HKD","LU2746668974.SGD","LU2237443549.SGD","BK4007","LU1363072403.SGD","LU1923622291.USD","IE00BKVL7J92.USD","LU0882574139.USD","ATHE","LU2211815571.USD","LU0053671581.USD","LU0971096721.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605047381","title":"Alterity Therapeutics highlights key 2026 objectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2605047381","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605047381?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:36","pubTimestamp":1768999016,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics (ATHE) issued a letter to shareholders, which read in part, “Our goal for 2025 was the successful completion of the Phase 2 p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-highlights-key-2026-objectives-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alterity-therapeutics-highlights-key-2026-objectives-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATHE","BK4139","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605910282","title":"Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2605910282","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605910282?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:25","pubTimestamp":1768998300,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and SAN FRANCISCO, Jan.  21, 2026  (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/21/3222672/0/en/Alterity-Therapeutics-Issues-Shareholder-Letter-Highlighting-2025-Progress-and-Key-Objectives-for-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","LU0053671581.USD","LU2211815571.USD","BK4139","BK4097","BK4007","BK4143","LU1815336091.USD","BK4539","LU2125909916.SGD","PRGS","LU2125909759.SGD","ATHE","LU0728928796.USD","LENZ","LU0757428866.USD","MSA","LU1923622291.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alteritytherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0146},{"period":"1month","weight":0.2234},{"period":"3month","weight":0.6028},{"period":"6month","weight":0.5978},{"period":"1year","weight":0.1446},{"period":"ytd","weight":0.6445}],"compareEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":-0.0166},{"period":"3month","weight":0.1366},{"period":"6month","weight":0.0622},{"period":"1year","weight":0.2084},{"period":"ytd","weight":0.0753}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.094427},{"month":2,"riseRate":0.375,"avgChangeRate":-0.06444},{"month":3,"riseRate":0.416667,"avgChangeRate":0.001978},{"month":4,"riseRate":0.541667,"avgChangeRate":-0.004691},{"month":5,"riseRate":0.375,"avgChangeRate":-0.042615},{"month":6,"riseRate":0.333333,"avgChangeRate":0.029602},{"month":7,"riseRate":0.565217,"avgChangeRate":0.095701},{"month":8,"riseRate":0.565217,"avgChangeRate":0.06488},{"month":9,"riseRate":0.26087,"avgChangeRate":-0.044502},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.065816},{"month":11,"riseRate":0.416667,"avgChangeRate":-0.021378},{"month":12,"riseRate":0.291667,"avgChangeRate":0.02698}],"exchange":"NASDAQ","name":"Alterity Therapeutics Limited","nameEN":"Alterity Therapeutics Limited","securityTypeName":"DR","adrRate":"1:600"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alterity Therapeutics Limited(ATHE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alterity Therapeutics Limited,ATHE,Alterity Therapeutics Limited股票,Alterity Therapeutics Limited股票老虎,Alterity Therapeutics Limited股票老虎国际,Alterity Therapeutics Limited行情,Alterity Therapeutics Limited股票行情,Alterity Therapeutics Limited股价,Alterity Therapeutics Limited股市,Alterity Therapeutics Limited股票价格,Alterity Therapeutics Limited股票交易,Alterity Therapeutics Limited股票购买,Alterity Therapeutics Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alterity Therapeutics Limited(ATHE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alterity Therapeutics Limited(ATHE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}